



*THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES*

## **Asep Completes Non-Brokered Private Placement of a \$330,000 Unsecured Convertible Debenture**

**VANCOUVER, BC, December 22, 2022 (CNW) — Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF)** is pleased to announce that it has a closed non-brokered private placement of an unsecured convertible debenture (the “**Debenture**”) in the principal amount of \$330,000 (the “**Offering**”).

The terms of the Debentures include, among other things:

- a maturity date (the “**Maturity Date**”) of two (2) years from the date of the closing;
- interest (“**Interest**”) at the rate of 10% per annum, payable upon the earlier of the Maturity Date or the date of any conversion thereof,
- the right of the holder, at any time on or before the Maturity Date, to elect to convert the outstanding principal amount and any accrued Interest, into common shares of the Company (each, a “**Share**”) at a price of \$0.33 per Share (the “**Conversion Price**”), and
- outstanding principal amount and any accrued Interest will be payable by the Company to the holder on the Maturity Date, and at the option of the Company may be paid by the issuance of Shares at the Conversion Price.

The proceeds will be used for working capital expenditures including operating expenses, research and development, pursuing advancement of the Issuer’s business plan, salaries and wages, investor relations and marketing fees, and professional fees.

All securities issued in the Offering are subject to a statutory hold period expiring April 23, 2023.

The Company is also pleased announce that it has retained bullVestor Medien GmbH (“**bullVestor**”) to provide strategic planning services to the Company. bullVestor has been engaged for strategic planning, procurement, advertising campaigns on financial ad networks and overseeing progress and results to heighten market and brand awareness for Asep Inc. and to broaden the Company's reach within the investment community.

bullVestor has been engaged by the Company for a period of six (6) months starting January 1, 2023 and ending on June 30, 2023 (the “**Term**”) bullVestor will be paid in one installment of EUR\$350,000 at the commencement of the Term.



## **ABOUT ASEP MEDICAL HOLDINGS INC.**

Asep Medical Holdings Inc. is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs. The Company is a consolidation of two existing private companies (Sepset Biosciences Inc. and ABT Innovations Inc.) that are both in the advanced development of both proprietary diagnostic tools, enabling the early and timely identification of severe sepsis as well as broad-spectrum therapeutic agents to address multidrug-resistant biofilm infections.

Sepset Biosciences Inc. is developing a diagnostic technology that involves a patient gene expression signature that predicts severe sepsis, one of the significant diseases leading to antibiotic failure since antibiotics are the primary treatment for sepsis. Despite this, sepsis is responsible for nearly 20% of all deaths on the planet. The Sepset<sup>ER</sup> test is a blood-based gene expression assay that is straightforward to implement, and results are obtained in about an hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in enabling diagnosis of severe sepsis within 1-2 hours of first clinical presentation (i.e., in the emergency room), while other diagnostics only provide diagnosis after 24-36 hours. Asep Inc. believes this will enable critical early decisions to be made by physicians regarding appropriate therapies and reduce overall morbidity and mortality due to sepsis.

ABT Innovations Inc.'s peptide technology covers a broad range of therapeutic applications, including bacterial biofilm infections (medical device infections, chronic infections, lung, bladder, wound, dental, skin, ear-nose and throat, sinusitis, orthopaedic, etc.), anti-inflammatories, anti-infective immune-modulators and vaccine adjuvants.

## **ABOUT BULLVESTOR MEDIEN GMBH**

bullVestor's business address is located at Gutenhofen 4 – 4300 Street, Valentin. For more information, please contact [kontakt@bullvestor.at](mailto:kontakt@bullvestor.at) (+43 (0) 7435-44077) or please visit bullVestor's website: [www.bullvestor.com](http://www.bullvestor.com).

## **FOR MORE INFORMATION, PLEASE CONTACT —**

Chris Dallin, Marketing Director  
ASEP Medical Holdings Inc.  
E. [chris@asepmedical.com](mailto:chris@asepmedical.com)  
T. +1 (604) 362-3654

*Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.*

## ***Forward-Looking Statements***

*This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release*



*include statements regarding the intended use of proceeds of the Offering. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements.*

*Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include, among other things: that the proceeds of the Offering may be used for uses other than as set out in this news release. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law, and the Company does not assume any liability for disclosure relating to any other company mentioned herein.*